| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79a9d2842de99fcc4fe8c049f6e3296c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate |
2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112759540-A |
| titleOfInvention |
Compound for resisting prostatic cancer and preparation method thereof |
| abstract |
The invention provides an anti-prostate cancer compound which is used as a VGSCs inhibitor and has a good killing effect on prostate cancer DU145 and prostate cancer PC3 cells. The preparation method is simple, has mild process conditions, and is suitable for large-scale production. |
| priorityDate |
2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |